{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T04:18:41Z","timestamp":1795148321995,"version":"4.10.3"},"reference-count":228,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-026-00711-z","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:02:56Z","timestamp":1781161376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chronic graft-versus-host disease"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3706-4959","authenticated-orcid":false,"given":"Yishan","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-9965","authenticated-orcid":false,"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3474-0002","authenticated-orcid":false,"given":"Florent","family":"Malard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"Aboudale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinaida","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"711_CR1","doi-asserted-by":"crossref","unstructured":"Wolff, D., Peric, Z. & Lawitschka, A. in The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies (eds Sureda, A. et al.) 395\u2013410 (Springer, 2024).","DOI":"10.1007\/978-3-031-44080-9_44"},{"key":"711_CR2","first-page":"504.e1","volume":"27","author":"CR Bachier","year":"2021","unstructured":"Bachier, C. R. et al. Epidemiology and treatment of chronic graft-versus-host disease post-allogeneic hematopoietic cell transplantation: a US claims analysis. Transpl. Cell Ther. 27, 504.e1\u2013504.e6 (2021).","journal-title":"Transpl. Cell Ther."},{"key":"711_CR3","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser, R. & Blazar, B. R. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N. Engl. J. Med. 377, 2565\u20132579 (2017).","journal-title":"N. Engl. J. Med."},{"key":"711_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1182\/hematology.2023000427","volume":"2023","author":"I Amanam","year":"2023","unstructured":"Amanam, I., Otoukesh, S., Al Malki, M. M. & Salhotra, A. Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies. Hematol. Am. Soc. Hematol Educ. Program. 2023, 164\u2013170 (2023).","journal-title":"Hematol. Am. Soc. Hematol Educ. Program."},{"key":"711_CR5","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","volume":"5","author":"Z DeFilipp","year":"2021","unstructured":"DeFilipp, Z. et al. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. Blood Adv. 5, 4278\u20134284 (2021).","journal-title":"Blood Adv."},{"key":"711_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia, M. H. et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol. Blood Marrow Transpl. 21, 389\u2013401.e1 (2015).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"711_CR7","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1002\/ajh.27040","volume":"98","author":"F Malard","year":"2023","unstructured":"Malard, F. & Mohty, M. Updates in chronic graft-versus-host disease management. Am. J. Hematol. 98, 1637\u20131644 (2023).","journal-title":"Am. J. Hematol."},{"key":"711_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","volume":"356","author":"AJ Ullmann","year":"2007","unstructured":"Ullmann, A. J. et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356, 335\u2013347 (2007).","journal-title":"N. Engl. J. Med."},{"key":"711_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","volume":"18","author":"JX Li","year":"2022","unstructured":"Li, J. X. & Cummins, C. L. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat. Rev. Endocrinol. 18, 540\u2013557 (2022).","journal-title":"Nat. Rev. Endocrinol."},{"key":"711_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S2213-8587(13)70045-7","volume":"1","author":"MJ Seibel","year":"2013","unstructured":"Seibel, M. J., Cooper, M. S. & Zhou, H. Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol. 1, 59\u201370 (2013).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"711_CR11","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1200\/JCO.22.02256","volume":"41","author":"R Zeiser","year":"2023","unstructured":"Zeiser, R. Novel approaches to the treatment of chronic graft-versus-host disease. J. Clin. Oncol. 41, 1820\u20131824 (2023).","journal-title":"J. Clin. Oncol."},{"key":"711_CR12","doi-asserted-by":"publisher","unstructured":"Zhao, Y. et al. A first-in-class JAK\/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD. Blood https:\/\/doi.org\/10.1182\/blood.2024026581 (2025).","DOI":"10.1182\/blood.2024026581"},{"key":"711_CR13","doi-asserted-by":"crossref","unstructured":"Boelens, J. J. et al. in The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies (eds Sureda, A. et al.) 219\u2013227 (Springer, 2024).","DOI":"10.1007\/978-3-031-44080-9_26"},{"key":"711_CR14","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood.2023022735","volume":"144","author":"JA Pidala","year":"2024","unstructured":"Pidala, J. A., Gooley, T. A., Luznik, L. & Blazar, B. R. Chronic graft-versus-host disease: unresolved complication or ancient history? Blood 144, 1363\u20131373 (2024).","journal-title":"Blood"},{"key":"711_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kroger","year":"2016","unstructured":"Kroger, N. et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N. Engl. J. Med. 374, 43\u201353 (2016).","journal-title":"N. Engl. J. Med."},{"key":"711_CR16","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","volume":"35","author":"RJ Soiffer","year":"2017","unstructured":"Soiffer, R. J. et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. J. Clin. Oncol. 35, 4003\u20134011 (2017).","journal-title":"J. Clin. Oncol."},{"key":"711_CR17","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","volume":"115","author":"L Luznik","year":"2010","unstructured":"Luznik, L. et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 115, 3224\u20133230 (2010).","journal-title":"Blood"},{"key":"711_CR18","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bolanos-Meade","year":"2023","unstructured":"Bolanos-Meade, J. et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N. Engl. J. Med. 388, 2338\u20132348 (2023).","journal-title":"N. Engl. J. Med."},{"key":"711_CR19","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1200\/JCO.21.02293","volume":"40","author":"L Luznik","year":"2022","unstructured":"Luznik, L. et al. Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies. J. Clin. Oncol. 40, 356\u2013368 (2022).","journal-title":"J. Clin. Oncol."},{"key":"711_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ajh.23594","volume":"89","author":"MJ Eckrich","year":"2014","unstructured":"Eckrich, M. J. et al. Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia. Am. J. Hematol. 89, 125\u2013129 (2014).","journal-title":"Am. J. Hematol."},{"key":"711_CR21","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1182\/bloodadvances.2019000386","volume":"3","author":"Y Inamoto","year":"2019","unstructured":"Inamoto, Y. et al. Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. Blood Adv. 3, 2764\u20132777 (2019).","journal-title":"Blood Adv."},{"key":"711_CR22","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41587-024-02348-3","volume":"43","author":"N Cieri","year":"2025","unstructured":"Cieri, N. et al. Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation. Nat. Biotechnol. 43, 971\u2013982 (2025).","journal-title":"Nat. Biotechnol."},{"key":"711_CR23","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.1182\/bloodadvances.2024013074","volume":"8","author":"N Farhadfar","year":"2024","unstructured":"Farhadfar, N. et al. Racial, ethnic, and socioeconomic diversity and outcomes of patients with graft-versus-host disease: a CIBMTR analysis. Blood Adv. 8, 4963\u20134976 (2024).","journal-title":"Blood Adv."},{"key":"711_CR24","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2008-05-158782","volume":"113","author":"JD Rizzo","year":"2009","unstructured":"Rizzo, J. D. et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113, 1175\u20131183 (2009).","journal-title":"Blood"},{"key":"711_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1182\/blood-2010-07-294629","volume":"117","author":"NS Majhail","year":"2011","unstructured":"Majhail, N. S. et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 117, 316\u2013322 (2011).","journal-title":"Blood"},{"key":"711_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamaoncol.2018.4934","volume":"5","author":"A Tichelli","year":"2019","unstructured":"Tichelli, A. et al. Evaluation of second solid cancers after hematopoietic stem cell transplantation in European patients. JAMA Oncol. 5, 229\u2013235 (2019).","journal-title":"JAMA Oncol."},{"key":"711_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7326\/0003-4819-155-1-201107050-00004","volume":"155","author":"EJ Chow","year":"2011","unstructured":"Chow, E. J. et al. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann. Intern. Med. 155, 21\u201332 (2011).","journal-title":"Ann. Intern. Med."},{"key":"711_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.bbmt.2016.08.019","volume":"23","author":"SH Armenian","year":"2017","unstructured":"Armenian, S. H. et al. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group report. Biol. Blood Marrow Transpl. 23, 201\u2013210 (2017).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"711_CR29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.bbmt.2018.09.031","volume":"25","author":"M Norkin","year":"2019","unstructured":"Norkin, M. et al. Characteristics of late fatal infections after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transpl. 25, 362\u2013368 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"711_CR30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jama.2009.1018","volume":"302","author":"KM Williams","year":"2009","unstructured":"Williams, K. M., Chien, J. W., Gladwin, M. T. & Pavletic, S. Z. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 302, 306\u2013314 (2009).","journal-title":"JAMA"},{"key":"711_CR31","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","volume":"110","author":"SJ Lee","year":"2007","unstructured":"Lee, S. J. et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110, 4576\u20134583 (2007).","journal-title":"Blood"},{"key":"711_CR32","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.bbmt.2009.11.011","volume":"16","author":"YL Kasamon","year":"2010","unstructured":"Kasamon, Y. L. et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol. Blood Marrow Transpl. 16, 482\u2013489 (2010).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"711_CR33","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1182\/blood-2014-04-571570","volume":"124","author":"Y Luo","year":"2014","unstructured":"Luo, Y. et al. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood 124, 2735\u20132743 (2014).","journal-title":"Blood"},{"key":"711_CR34","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1182\/blood.2021013443","volume":"139","author":"EJ Fuchs","year":"2022","unstructured":"Fuchs, E. J. et al. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. Blood 139, 1452\u20131468 (2022).","journal-title":"Blood"},{"key":"711_CR35","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1053\/bbmt.2002.v8.abbmt080674","volume":"8","author":"M Remberger","year":"2002","unstructured":"Remberger, M. et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transpl. 8, 674\u2013682 (2002).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"711_CR36","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1182\/bloodadvances.2024013442","volume":"8","author":"M Tamaki","year":"2024","unstructured":"Tamaki, M. et al. Associations between acute and chronic graft-versus-host disease. Blood Adv. 8, 4250\u20134261 (2024).","journal-title":"Blood Adv."},{"key":"711_CR37","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1182\/bloodadvances.2022009505","volume":"7","author":"S Herzog","year":"2023","unstructured":"Herzog, S. et al. Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes. Blood Adv. 7, 3644\u20133650 (2023).","journal-title":"Blood Adv."},{"key":"711_CR38","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti, C. et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N. Engl. J. Med. 367, 1487\u20131496 (2012).","journal-title":"N. Engl. J. Med."},{"key":"711_CR39","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1001\/jamaoncol.2016.2520","volume":"2","author":"SJ Lee","year":"2016","unstructured":"Lee, S. J. et al. Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial. JAMA Oncol. 2, 1583\u20131589 (2016).","journal-title":"JAMA Oncol."},{"key":"711_CR40","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1365-2141.2007.06543.x","volume":"137","author":"S Ozawa","year":"2007","unstructured":"Ozawa, S. et al. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Br. J. Haematol. 137, 142\u2013151 (2007).","journal-title":"Br. J. Haematol."},{"key":"711_CR41","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1182\/blood-2011-04-350249","volume":"118","author":"KJ Martires","year":"2011","unstructured":"Martires, K. J. et al. Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood 118, 4250\u20134257 (2011).","journal-title":"Blood"},{"key":"711_CR42","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1182\/blood-2012-10-464198","volume":"121","author":"Y Inamoto","year":"2013","unstructured":"Inamoto, Y. et al. Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood 121, 5098\u20135103 (2013).","journal-title":"Blood"},{"key":"711_CR43","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1182\/blood.2023023697","volume":"143","author":"J Sanz","year":"2024","unstructured":"Sanz, J. et al. Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT. Blood 143, 2534\u20132543 (2024).","journal-title":"Blood"},{"key":"711_CR44","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1182\/bloodadvances.2024013756","volume":"8","author":"SR Spellman","year":"2024","unstructured":"Spellman, S. R. et al. Novel machine learning technique further clarifies unrelated donor selection to optimize transplantation outcomes. Blood Adv. 8, 6082\u20136087 (2024).","journal-title":"Blood Adv."},{"key":"711_CR45","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1182\/blood-2015-10-672345","volume":"127","author":"AC Alho","year":"2016","unstructured":"Alho, A. C. et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood 127, 646\u2013657 (2016).","journal-title":"Blood"},{"key":"711_CR46","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41409-026-02817-0","volume":"61","author":"F Malard","year":"2026","unstructured":"Malard, F. et al. Chronic graft-versus-host disease: current situation and unmet needs \u2014 a European position statement. Bone Marrow Transplant. 61, 373\u2013384 (2026).","journal-title":"Bone Marrow Transplant."},{"key":"711_CR47","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1164\/rccm.202506-1352ST","volume":"211","author":"GS Cheng","year":"2025","unstructured":"Cheng, G. S. et al. Addressing knowledge gaps in the early detection of bronchiolitis obliterans syndrome after hematopoietic cell transplantation: an official American Thoracic Society research statement. Am. J. Respir. Crit. Care Med. 211, 1369\u20131390 (2025).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"711_CR48","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41409-023-02151-9","volume":"59","author":"QS Huang","year":"2024","unstructured":"Huang, Q. S. et al. Clinical risk factors and prognostic model for patients with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Bone Marrow Transpl. 59, 239\u2013246 (2024).","journal-title":"Bone Marrow Transpl."},{"key":"711_CR49","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.289266","author":"PA Cant\u00f2","year":"2026","unstructured":"Cant\u00f2, P. A. et al. Chronic graft-versus-host disease in the era of post-transplant cyclophosphamide. Haematologica https:\/\/doi.org\/10.3324\/haematol.2025.289266 (2026).","journal-title":"Haematologica"},{"key":"711_CR50","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1200\/JCO.24.00184","volume":"42","author":"BC Shaffer","year":"2024","unstructured":"Shaffer, B. C. et al. Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors. J. Clin. Oncol. 42, 3277\u20133286 (2024).","journal-title":"J. Clin. Oncol."},{"key":"711_CR51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2025.4551","volume":"12","author":"RS Mehta","year":"2025","unstructured":"Mehta, R. S. et al. Unrelated donor age and recipient outcomes after posttransplant cyclophosphamide vs conventional prophylaxis. JAMA Oncol. 12, 28\u201337 (2025).","journal-title":"JAMA Oncol."},{"key":"711_CR52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","volume":"129","author":"KP MacDonald","year":"2017","unstructured":"MacDonald, K. P., Hill, G. R. & Blazar, B. R. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood 129, 13\u201321 (2017).","journal-title":"Blood"},{"key":"711_CR53","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1182\/blood.2024024540","volume":"145","author":"Y Kambara","year":"2025","unstructured":"Kambara, Y. et al. Oral inflammation and microbiome dysbiosis exacerbate chronic graft-versus-host disease. Blood 145, 881\u2013896 (2025).","journal-title":"Blood"},{"key":"711_CR54","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1182\/blood.2019003369","volume":"136","author":"KA Markey","year":"2020","unstructured":"Markey, K. A. et al. The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. Blood 136, 130\u2013136 (2020).","journal-title":"Blood"},{"key":"711_CR55","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbmt.2007.10.009","volume":"14","author":"HT Greinix","year":"2008","unstructured":"Greinix, H. T. et al. Elevated numbers of immature\/transitional CD21\u2212 B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol. Blood Marrow Transpl. 14, 208\u2013219 (2008).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"711_CR56","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.169732","volume":"8","author":"JC Poe","year":"2023","unstructured":"Poe, J. C. et al. Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHD. JCI Insight 8, e169732 (2023).","journal-title":"JCI Insight"},{"key":"711_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq3277","volume":"7","author":"R Yang","year":"2022","unstructured":"Yang, R. et al. Human T-bet governs the generation of a distinct subset of CD11chighCD21low B cells. Sci. Immunol. 7, eabq3277 (2022).","journal-title":"Sci. Immunol."},{"key":"711_CR58","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1182\/blood-2014-04-571125","volume":"124","author":"A Khoder","year":"2014","unstructured":"Khoder, A. et al. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood 124, 2034\u20132045 (2014).","journal-title":"Blood"},{"key":"711_CR59","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1182\/blood-2016-01-695122","volume":"128","author":"A Sarvaria","year":"2016","unstructured":"Sarvaria, A. et al. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood 128, 1346\u20131361 (2016).","journal-title":"Blood"},{"key":"711_CR60","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1182\/blood-2017-05-782466","volume":"130","author":"JC Poe","year":"2017","unstructured":"Poe, J. C. et al. An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. Blood 130, 2131\u20132145 (2017).","journal-title":"Blood"},{"key":"711_CR61","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1182\/blood.2020008040","volume":"137","author":"W Jia","year":"2021","unstructured":"Jia, W. et al. BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation. Blood 137, 2544\u20132557 (2021).","journal-title":"Blood"},{"key":"711_CR62","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat8410","volume":"10","author":"S Tugues","year":"2018","unstructured":"Tugues, S. et al. Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells. Sci. Transl. Med. 10, eaat8410 (2018).","journal-title":"Sci. Transl. Med."},{"key":"711_CR63","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1182\/blood.2019000396","volume":"134","author":"AN Wilkinson","year":"2019","unstructured":"Wilkinson, A. N. et al. IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling. Blood 134, 2092\u20132106 (2019).","journal-title":"Blood"},{"key":"711_CR64","doi-asserted-by":"publisher","first-page":"5249","DOI":"10.1182\/blood-2009-11-255422","volume":"115","author":"R Das","year":"2010","unstructured":"Das, R. et al. Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses. Blood 115, 5249\u20135258 (2010).","journal-title":"Blood"},{"key":"711_CR65","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1182\/blood-2007-05-091074","volume":"110","author":"X Chen","year":"2007","unstructured":"Chen, X. et al. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 110, 3804\u20133813 (2007).","journal-title":"Blood"},{"key":"711_CR66","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/bmt.2013.215","volume":"49","author":"F Malard","year":"2014","unstructured":"Malard, F. et al. Increased Th17\/Treg ratio in chronic liver GVHD. Bone Marrow Transpl. 49, 539\u2013544 (2014).","journal-title":"Bone Marrow Transpl."},{"key":"711_CR67","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.immuni.2023.01.003","volume":"56","author":"F Sacirbegovic","year":"2023","unstructured":"Sacirbegovic, F. et al. Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells. Immunity 56, 369\u2013385.e6 (2023).","journal-title":"Immunity"},{"key":"711_CR68","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe2634","volume":"7","author":"GP de Almeida","year":"2022","unstructured":"de Almeida, G. P. et al. Human skin-resident host T cells can persist long term after allogeneic stem cell transplantation and maintain recirculation potential. Sci. Immunol. 7, eabe2634 (2022).","journal-title":"Sci. Immunol."},{"key":"711_CR69","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood-2017-01-758854","volume":"129","author":"J Du","year":"2017","unstructured":"Du, J. et al. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-\u03b2 production. Blood 129, 2570\u20132580 (2017).","journal-title":"Blood"},{"key":"711_CR70","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2011-07-364414","volume":"119","author":"M Srinivasan","year":"2012","unstructured":"Srinivasan, M. et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood 119, 1570\u20131580 (2012).","journal-title":"Blood"},{"key":"711_CR71","doi-asserted-by":"publisher","first-page":"488","DOI":"10.4049\/jimmunol.1300657","volume":"191","author":"T Wu","year":"2013","unstructured":"Wu, T. et al. Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells. J. Immunol. 191, 488\u2013499 (2013).","journal-title":"J. Immunol."},{"key":"711_CR72","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/hon.2255","volume":"35","author":"Y Hu","year":"2017","unstructured":"Hu, Y. et al. Reduction of Foxp3+ T cell subsets involved in incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Hematol. Oncol. 35, 118\u2013124 (2017).","journal-title":"Hematol. Oncol."},{"key":"711_CR73","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1182\/blood-2014-03-562231","volume":"123","author":"R Flynn","year":"2014","unstructured":"Flynn, R. et al. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood 123, 3988\u20133998 (2014).","journal-title":"Blood"},{"key":"711_CR74","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1182\/blood-2015-09-668251","volume":"127","author":"A Kariminia","year":"2016","unstructured":"Kariminia, A. et al. Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. Blood 127, 3082\u20133091 (2016).","journal-title":"Blood"},{"key":"711_CR75","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1182\/blood-2016-11-752444","volume":"129","author":"J Du","year":"2017","unstructured":"Du, J. et al. Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129, 3121\u20133125 (2017).","journal-title":"Blood"},{"key":"711_CR76","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1182\/blood-2015-12-688739","volume":"127","author":"F Malard","year":"2016","unstructured":"Malard, F. et al. Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival. Blood 127, 1828\u20131835 (2016).","journal-title":"Blood"},{"key":"711_CR77","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1182\/blood.2021010887","volume":"138","author":"K Maas-Bauer","year":"2021","unstructured":"Maas-Bauer, K. et al. Invariant natural killer T-cell subsets have diverse graft-versus-host-disease-preventing and antitumor effects. Blood 138, 858\u2013870 (2021).","journal-title":"Blood"},{"key":"711_CR78","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1172\/JCI133102","volume":"130","author":"S Dertschnig","year":"2020","unstructured":"Dertschnig, S. et al. Graft-versus-host disease reduces lymph node display of tissue-restricted self-antigens and promotes autoimmunity. J. Clin. Invest. 130, 1896\u20131911 (2020).","journal-title":"J. Clin. Invest."},{"key":"711_CR79","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2015-12-688895","volume":"127","author":"E Forcade","year":"2016","unstructured":"Forcade, E. et al. Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood 127, 2489\u20132497 (2016).","journal-title":"Blood"},{"key":"711_CR80","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jaut.2019.03.006","volume":"100","author":"H Jin","year":"2019","unstructured":"Jin, H. et al. Expansion of circulating extrafollicular helper T-like cells in patients with chronic graft-versus-host disease. J. Autoimmun. 100, 95\u2013104 (2019).","journal-title":"J. Autoimmun."},{"key":"711_CR81","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1182\/blood.2022016581","volume":"140","author":"X Kong","year":"2022","unstructured":"Kong, X. et al. Trafficking between clonally related peripheral T-helper cells and tissue-resident T-helper cells in chronic GVHD. Blood 140, 2740\u20132753 (2022).","journal-title":"Blood"},{"key":"711_CR82","doi-asserted-by":"publisher","unstructured":"Kong, X. et al. Tissue-resident PSGL1loCD4+ T cells promote B cell differentiation and chronic graft-versus-host disease-associated autoimmunity. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI135468 (2021).","DOI":"10.1172\/JCI135468"},{"key":"711_CR83","doi-asserted-by":"publisher","first-page":"657","DOI":"10.21147\/j.issn.1000-9604.2025.05.01","volume":"37","author":"Z Chen","year":"2025","unstructured":"Chen, Z. et al. Gut microbiota and acute graft-versus-host disease. Chin. J. Cancer Res. 37, 657\u2013666 (2025).","journal-title":"Chin. J. Cancer Res."},{"key":"711_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32960-3","volume":"13","author":"Y Hu","year":"2022","unstructured":"Hu, Y. et al. CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. Nat. Commun. 13, 5313 (2022).","journal-title":"Nat. Commun."},{"key":"711_CR85","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1038\/s41409-021-01249-2","volume":"56","author":"T Konishi","year":"2021","unstructured":"Konishi, T. et al. Low diversity of gut microbiota in the early phase of post-bone marrow transplantation increases the risk of chronic graft-versus-host disease. Bone Marrow Transpl. 56, 1728\u20131731 (2021).","journal-title":"Bone Marrow Transpl."},{"key":"711_CR86","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1182\/blood.2024027301","volume":"145","author":"KM Habenicht","year":"2025","unstructured":"Habenicht, K. M. et al. Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD. Blood 145, 3178\u20133188 (2025).","journal-title":"Blood"},{"key":"711_CR87","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1182\/blood-2013-10-533562","volume":"123","author":"JL Allen","year":"2014","unstructured":"Allen, J. L. et al. Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood 123, 2108\u20132115 (2014).","journal-title":"Blood"},{"key":"711_CR88","unstructured":"US Food and Drug Administration. FDA approves treatment for chronic graft versus host disease. FDA Newsroom (2 August 2017)."},{"key":"711_CR89","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/blood-2006-01-0233","volume":"108","author":"C Cutler","year":"2006","unstructured":"Cutler, C. et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108, 756\u2013762 (2006).","journal-title":"Blood"},{"key":"711_CR90","first-page":"179.e1","volume":"29","author":"C Lin","year":"2023","unstructured":"Lin, C. et al. A phase I trial of SYK inhibition with fostamatinib in the prevention and treatment of chronic graft-versus-host disease. Transpl. Cell Ther. 29, 179.e1\u2013179.e10 (2023).","journal-title":"Transpl. Cell Ther."},{"key":"711_CR91","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jaci.2024.09.020","volume":"155","author":"S Samra","year":"2025","unstructured":"Samra, S., Bergerson, J. R. E., Freeman, A. F. & Turvey, S. E. JAK-STAT signaling pathway, immunodeficiency, inflammation, immune dysregulation, and inborn errors of immunity. J. Allergy Clin. Immunol. 155, 357\u2013367 (2025).","journal-title":"J. Allergy Clin. Immunol."},{"key":"711_CR92","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","volume":"123","author":"S Spoerl","year":"2014","unstructured":"Spoerl, S. et al. Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease. Blood 123, 3832\u20133842 (2014).","journal-title":"Blood"},{"key":"711_CR93","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1172\/JCI42856","volume":"120","author":"PS Biswas","year":"2010","unstructured":"Biswas, P. S. et al. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J. Clin. Invest. 120, 3280\u20133295 (2010).","journal-title":"J. Clin. Invest."},{"key":"711_CR94","doi-asserted-by":"publisher","first-page":"ra73","DOI":"10.1126\/scisignal.aad8953","volume":"9","author":"JM Weiss","year":"2016","unstructured":"Weiss, J. M. et al. ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings. Sci. Signal. 9, ra73 (2016).","journal-title":"Sci. Signal."},{"key":"711_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108823","volume":"230","author":"A Zanin-Zhorov","year":"2021","unstructured":"Zanin-Zhorov, A. & Blazar, B. R. ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease. Clin. Immunol. 230, 108823 (2021).","journal-title":"Clin. Immunol."},{"key":"711_CR96","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/blood-2015-10-678706","volume":"127","author":"R Flynn","year":"2016","unstructured":"Flynn, R. et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood 127, 2144\u20132154 (2016).","journal-title":"Blood"},{"key":"711_CR97","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1172\/JCI75935","volume":"124","author":"KA Alexander","year":"2014","unstructured":"Alexander, K. A. et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J. Clin. Invest. 124, 4266\u20134280 (2014).","journal-title":"J. Clin. Invest."},{"key":"711_CR98","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.22.00958","volume":"41","author":"CL Kitko","year":"2023","unstructured":"Kitko, C. L. et al. Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study. J. Clin. Oncol. 41, 1864\u20131875 (2023).","journal-title":"J. Clin. Oncol."},{"key":"711_CR99","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1182\/blood.2023022040","volume":"143","author":"RC Adams","year":"2024","unstructured":"Adams, R. C. et al. CSF1R inhibition promotes neuroinflammation and behavioral deficits during graft-versus-host disease in mice. Blood 143, 912\u2013929 (2024).","journal-title":"Blood"},{"key":"711_CR100","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1182\/blood-2018-01-822957","volume":"131","author":"H Major-Monfried","year":"2018","unstructured":"Major-Monfried, H. et al. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood 131, 2846\u20132855 (2018).","journal-title":"Blood"},{"key":"711_CR101","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1158\/1078-0432.CCR-07-1290","volume":"13","author":"S Sarantopoulos","year":"2007","unstructured":"Sarantopoulos, S. et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin. Cancer Res. 13, 6107\u20136114 (2007).","journal-title":"Clin. Cancer Res."},{"key":"711_CR102","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.bbmt.2017.04.019","volume":"23","author":"Y Inamoto","year":"2017","unstructured":"Inamoto, Y. et al. Association of plasma CD163 concentration with de novo-onset chronic graft-versus-host disease. Biol. Blood Marrow Transpl. 23, 1250\u20131256 (2017).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"711_CR103","doi-asserted-by":"publisher","DOI":"10.1172\/JCI168575","volume":"133","author":"BR Logan","year":"2023","unstructured":"Logan, B. R. et al. Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death. J. Clin. Invest. 133, e168575 (2023).","journal-title":"J. Clin. Invest."},{"key":"711_CR104","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1200\/JCO.2015.65.9615","volume":"34","author":"J Yu","year":"2016","unstructured":"Yu, J. et al. Biomarker panel for chronic graft-versus-host disease. J. Clin. Oncol. 34, 2583\u20132590 (2016).","journal-title":"J. Clin. Oncol."},{"key":"711_CR105","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1182\/blood-2017-08-800623","volume":"131","author":"J Du","year":"2018","unstructured":"Du, J. et al. Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. Blood 131, 1743\u20131754 (2018).","journal-title":"Blood"},{"key":"711_CR106","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163541","volume":"134","author":"B Avni","year":"2024","unstructured":"Avni, B. et al. Chronic graft-versus-host disease detected by tissue-specific cell-free DNA methylation biomarkers. J. Clin. Invest. 134, e163541 (2024).","journal-title":"J. Clin. Invest."},{"key":"711_CR107","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1182\/blood.2021013244","volume":"139","author":"D Subburaj","year":"2022","unstructured":"Subburaj, D. et al. Metabolomic identification of \u03b1-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease. Blood 139, 287\u2013299 (2022).","journal-title":"Blood"},{"key":"711_CR108","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1182\/blood.2024025337","volume":"145","author":"JR Boiko","year":"2025","unstructured":"Boiko, J. R. et al. Defining pathogenic IL-17 and CSF-1 gene expression signatures in chronic graft-versus-host disease. Blood 145, 2214\u20132228 (2025).","journal-title":"Blood"},{"key":"711_CR109","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood.2025028625","volume":"147","author":"B Ng","year":"2026","unstructured":"Ng, B. et al. Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation. Blood 147, 241\u2013253 (2026).","journal-title":"Blood"},{"key":"711_CR110","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","volume":"21","author":"SJ Lee","year":"2015","unstructured":"Lee, S. J. et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol. Blood Marrow Transpl. 21, 984\u2013999 (2015).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"711_CR111","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamadermatol.2022.6624","volume":"159","author":"E Baumrin","year":"2023","unstructured":"Baumrin, E. et al. Prognostic value of cutaneous disease severity estimates on survival outcomes in patients with chronic graft-vs-host disease. JAMA Dermatol. 159, 393\u2013402 (2023).","journal-title":"JAMA Dermatol."},{"key":"711_CR112","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41409-018-0340-0","volume":"54","author":"Y Inamoto","year":"2019","unstructured":"Inamoto, Y. et al. Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transpl. 54, 662\u2013673 (2019).","journal-title":"Bone Marrow Transpl."},{"key":"711_CR113","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ajo.2020.05.035","volume":"218","author":"S Sinha","year":"2020","unstructured":"Sinha, S. et al. Prevalence of persistent corneal epithelial defects in chronic ocular graft-versus-host disease. Am. J. Ophthalmol. 218, 296\u2013303 (2020).","journal-title":"Am. J. Ophthalmol."},{"key":"711_CR114","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00261-013-0072-y","volume":"39","author":"OR Brook","year":"2014","unstructured":"Brook, O. R. et al. Pancreatic atrophy in patients with chronic graft-versus-host disease. Abdom. Imaging 39, 342\u2013347 (2014).","journal-title":"Abdom. Imaging"},{"key":"711_CR115","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01727-2023","volume":"63","author":"S Bos","year":"2024","unstructured":"Bos, S. et al. ERS\/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults. Eur. Respir. J. 63, 2301727 (2024).","journal-title":"Eur. Respir. J."},{"key":"711_CR116","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/bloodadvances.2019000918","volume":"4","author":"Y Inamoto","year":"2020","unstructured":"Inamoto, Y. et al. Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. Blood Adv. 4, 40\u201346 (2020).","journal-title":"Blood Adv."},{"key":"711_CR117","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/art.38293","volume":"66","author":"Y Inamoto","year":"2014","unstructured":"Inamoto, Y. et al. Assessment of joint and fascia manifestations in chronic graft-versus-host disease. Arthritis Rheumatol. 66, 1044\u20131052 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"711_CR118","first-page":"545","volume":"27","author":"CL Kitko","year":"2021","unstructured":"Kitko, C. L. et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group report. Transpl. Cell Ther. 27, 545\u2013557 (2021).","journal-title":"Transpl. Cell Ther."},{"key":"711_CR119","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/bmt.2016.315","volume":"52","author":"BK Hamilton","year":"2017","unstructured":"Hamilton, B. K., Goje, O., Savani, B. N., Majhail, N. S. & Stratton, P. Clinical management of genital chronic GvHD. Bone Marrow Transpl. 52, 803\u2013810 (2017).","journal-title":"Bone Marrow Transpl."},{"key":"711_CR120","first-page":"678.e1","volume":"31","author":"SJ Lee","year":"2025","unstructured":"Lee, S. J. et al. NIH Chronic Graft-Versus-Host Disease Consensus Conference 2025 update. Transpl. Cell Ther. 31, 678.e1\u2013678.e16 (2025).","journal-title":"Transpl. Cell Ther."},{"key":"711_CR121","first-page":"S491","volume":"30","author":"C Cutler","year":"2024","unstructured":"Cutler, C. Forward to chronic GVHD supplement in transplantation and cellular therapy. Transpl. Cell Ther. 30, S491\u2013S492 (2024).","journal-title":"Transpl. Cell Ther."},{"key":"711_CR122","first-page":"349","volume":"30","author":"SJ Rotz","year":"2024","unstructured":"Rotz, S. J. et al. International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update. Transpl. Cell Ther. 30, 349\u2013385 (2024).","journal-title":"Transpl. Cell Ther."},{"key":"711_CR123","first-page":"759.e1","volume":"27","author":"Y Inamoto","year":"2021","unstructured":"Inamoto, Y. et al. Relevance of plasma matrix metalloproteinase-9 for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation. Transpl. Cell Ther. 27, 759.e1\u2013759.e8 (2021).","journal-title":"Transpl. Cell Ther."},{"key":"711_CR124","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1111\/ajt.15814","volume":"20","author":"GS Cheng","year":"2020","unstructured":"Cheng, G. S. et al. Multicenter evaluation of parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Am. J. Transpl. 20, 2198\u20132205 (2020).","journal-title":"Am. J. Transpl."},{"key":"711_CR125","first-page":"616.e1","volume":"27","author":"J Turner","year":"2021","unstructured":"Turner, J. et al. Home spirometry telemonitoring for early detection of bronchiolitis obliterans syndrome in patients with chronic graft-versus-host disease. Transpl. Cell Ther. 27, 616.e1\u2013616.e6 (2021).","journal-title":"Transpl. Cell Ther."},{"key":"711_CR126","first-page":"271.e1","volume":"27","author":"GL Chen","year":"2021","unstructured":"Chen, G. L. et al. Optical coherence tomography for quantifying human cutaneous chronic graft-versus-host disease. Transpl. Cell Ther. 27, 271.e1\u2013271.e8 (2021).","journal-title":"Transpl. Cell Ther."},{"key":"711_CR127","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1111\/bjh.18141","volume":"197","author":"A McNeil","year":"2022","unstructured":"McNeil, A. et al. Artificial intelligence recognition of cutaneous chronic graft-versus-host disease by a deep learning neural network. Br. J. Haematol. 197, e69\u2013e72 (2022).","journal-title":"Br. J. Haematol."},{"key":"711_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00438-1","volume":"9","author":"F Malard","year":"2023","unstructured":"Malard, F., Holler, E., Sandmaier, B. M., Huang, H. & Mohty, M. Acute graft-versus-host disease. Nat. Rev. Dis. Primers 9, 27 (2023).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"711_CR129","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1182\/blood.2023019875","volume":"142","author":"H Senjo","year":"2023","unstructured":"Senjo, H. et al. Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT. Blood 142, 477\u2013492 (2023).","journal-title":"Blood"},{"key":"711_CR130","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170125","volume":"134","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD. J. Clin. Invest. 134, e170125 (2024).","journal-title":"J. Clin. Invest."},{"key":"711_CR131","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood.2023023660","volume":"144","author":"LS Kean","year":"2024","unstructured":"Kean, L. S. et al. Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation. Blood 144, 1834\u20131845 (2024).","journal-title":"Blood"},{"key":"711_CR132","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1182\/blood.2023020035","volume":"142","author":"T Takahashi","year":"2023","unstructured":"Takahashi, T. et al. Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events. Blood 142, 700\u2013710 (2023).","journal-title":"Blood"},{"key":"711_CR133","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04380740 (2026)."},{"key":"711_CR134","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood.2024026497","volume":"145","author":"R Abboud","year":"2025","unstructured":"Abboud, R. et al. Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation. Blood 145, 1382\u20131394 (2025).","journal-title":"Blood"},{"key":"711_CR135","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1182\/blood.2024028005","volume":"145","author":"Z DeFilipp","year":"2025","unstructured":"DeFilipp, Z. et al. Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT. Blood 145, 2312\u20132316 (2025).","journal-title":"Blood"},{"key":"711_CR136","unstructured":"Blood & Marrow Transplant Clinical Trials Network. A Randomized, Multicenter, Phase III Trial of Tacrolimus\/Methotrexate\/Ruxolitinib Versus Post-Transplant Cyclophosphamide\/Tacrolimus\/Mycophenolate Mofetil in Non-Myeloablative\/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation https:\/\/bmtctn.net\/bmt-ctn-studies\/2203 (BMTCTN, 2026)."},{"key":"711_CR137","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1038\/s41591-024-03016-4","volume":"30","author":"YB Chen","year":"2024","unstructured":"Chen, Y. B. et al. Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial. Nat. Med. 30, 2277\u20132287 (2024).","journal-title":"Nat. Med."},{"key":"711_CR138","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood.2024028303","volume":"146","author":"E Schulz","year":"2025","unstructured":"Schulz, E. et al. Phase 1\/2 study of high-dose palifermin for GVHD prophylaxis in patients undergoing HLA-matched unrelated donor HCT. Blood 146, 944\u2013950 (2025).","journal-title":"Blood"},{"key":"711_CR139","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/blood.2023020250","volume":"143","author":"J Magenau","year":"2024","unstructured":"Magenau, J. et al. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. Blood 143, 21\u201331 (2024).","journal-title":"Blood"},{"key":"711_CR140","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.1182\/blood-2011-01-329821","volume":"117","author":"G Socie","year":"2011","unstructured":"Socie, G. et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-fresenius. Blood 117, 6375\u20136382 (2011).","journal-title":"Blood"},{"key":"711_CR141","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3324\/haematol.2016.148510","volume":"102","author":"F Baron","year":"2017","unstructured":"Baron, F. et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica 102, 224\u2013234 (2017).","journal-title":"Haematologica"},{"key":"711_CR142","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJMoa2503189","volume":"393","author":"DJ Curtis","year":"2025","unstructured":"Curtis, D. J. et al. Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin. N. Engl. J. Med. 393, 243\u2013254 (2025).","journal-title":"N. Engl. J. Med."},{"key":"711_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00990-3","volume":"14","author":"E Brissot","year":"2024","unstructured":"Brissot, E. et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10\/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial. Blood Cancer J. 14, 31 (2024).","journal-title":"Blood Cancer J."},{"key":"711_CR144","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025032569","author":"J Yang Sr.","year":"2026","unstructured":"Yang, J. Sr. et al. Randomized trial of GvHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy. Blood https:\/\/doi.org\/10.1182\/blood.2025032569 (2026).","journal-title":"Blood"},{"key":"711_CR145","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05153226 (2024)."},{"key":"711_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2025.102662","volume":"97","author":"S Fuji","year":"2025","unstructured":"Fuji, S. & Ohmoto, A. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis: current status and optimization strategies. Curr. Opin. Immunol. 97, 102662 (2025).","journal-title":"Curr. Opin. Immunol."},{"key":"711_CR147","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1182\/blood-2015-07-659672","volume":"127","author":"RA Marsh","year":"2016","unstructured":"Marsh, R. A. et al. Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT. Blood 127, 503\u2013512 (2016).","journal-title":"Blood"},{"key":"711_CR148","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/ajh.25314","volume":"94","author":"S Samarasinghe","year":"2019","unstructured":"Samarasinghe, S. et al. Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: a study on behalf of the European Blood and Marrow Transplant Severe Aplastic Anemia Working Party. Am. J. Hematol. 94, 80\u201386 (2019).","journal-title":"Am. J. Hematol."},{"key":"711_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01567-0","volume":"17","author":"S Naik","year":"2024","unstructured":"Naik, S. et al. Memory T-cell enriched haploidentical transplantation with NK cell addback results in promising long-term outcomes: a phase II trial. J. Hematol. Oncol. 17, 50 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"711_CR150","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1182\/blood-2014-09-599423","volume":"125","author":"I Airoldi","year":"2015","unstructured":"Airoldi, I. et al. \u03b3\u03b4 T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-\u03b1\u03b2+\/CD19+ lymphocytes. Blood 125, 2349\u20132358 (2015).","journal-title":"Blood"},{"key":"711_CR151","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1182\/blood.2023021336","volume":"143","author":"P Merli","year":"2024","unstructured":"Merli, P. et al. TCR\u03b1\u03b2\/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis. Blood 143, 279\u2013289 (2024).","journal-title":"Blood"},{"key":"711_CR152","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nm915","volume":"9","author":"M Edinger","year":"2003","unstructured":"Edinger, M. et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9, 1144\u20131150 (2003).","journal-title":"Nat. Med."},{"key":"711_CR153","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jamaoncol.2023.5757","volume":"10","author":"R Huang","year":"2024","unstructured":"Huang, R. et al. Mesenchymal stem cells for prophylaxis of chronic graft-vs-host disease after haploidentical hematopoietic stem cell transplant: an open-label randomized clinical trial. JAMA Oncol. 10, 220\u2013226 (2024).","journal-title":"JAMA Oncol."},{"key":"711_CR154","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1200\/JCO.2015.65.3642","volume":"34","author":"L Gao","year":"2016","unstructured":"Gao, L. et al. Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation. J. Clin. Oncol. 34, 2843\u20132850 (2016).","journal-title":"J. Clin. Oncol."},{"key":"711_CR155","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO-24-02119","volume":"43","author":"H Yao","year":"2025","unstructured":"Yao, H. et al. Sequential infusion of mesenchymal stem cell for graft-versus-host disease prevention in haploidentical hematopoietic stem cell transplantation: an open-label, multicenter, randomized controlled clinical trial. J. Clin. Oncol. 43, 1997\u20132006 (2025).","journal-title":"J. Clin. Oncol."},{"key":"711_CR156","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1200\/JCO-24-02477","volume":"43","author":"R Zeiser","year":"2025","unstructured":"Zeiser, R. et al. Ruxolitinib in patients with corticosteroid-refractory or corticosteroid-dependent chronic graft-versus-host disease: 3-year final analysis of the phase III REACH3 study. J. Clin. Oncol. 43, 2566\u20132571 (2025).","journal-title":"J. Clin. Oncol."},{"key":"711_CR157","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","volume":"53","author":"HM Schoemans","year":"2018","unstructured":"Schoemans, H. M. et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transpl. 53, 1401\u20131415 (2018).","journal-title":"Bone Marrow Transpl."},{"key":"711_CR158","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser, R. et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N. Engl. J. Med. 385, 228\u2013238 (2021).","journal-title":"N. Engl. J. Med."},{"key":"711_CR159","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.34750","volume":"4","author":"H Wu","year":"2021","unstructured":"Wu, H. et al. Evaluation of ruxolitinib for steroid-refractory chronic graft-vs-host disease after allogeneic hematopoietic stem cell transplantation. JAMA Netw. Open\u00a04, e2034750 (2021).","journal-title":"JAMA Netw. Open"},{"key":"711_CR160","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack, O. et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 11, e147\u2013e159 (2024).","journal-title":"Lancet Haematol."},{"key":"711_CR161","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1200\/JCO.20.02754","volume":"39","author":"M Jagasia","year":"2021","unstructured":"Jagasia, M. et al. ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease. J. Clin. Oncol. 39, 1888\u20131898 (2021).","journal-title":"J. Clin. Oncol."},{"key":"711_CR162","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1182\/blood.2021012021","volume":"138","author":"C Cutler","year":"2021","unstructured":"Cutler, C. et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study. Blood 138, 2278\u20132289 (2021).","journal-title":"Blood"},{"key":"711_CR163","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-21-4176","volume":"28","author":"D Przepiorka","year":"2022","unstructured":"Przepiorka, D. et al. FDA approval summary: belumosudil for adult and pediatric patients 12 years and older with chronic GvHD after two or more prior lines of systemic therapy. Clin. Cancer Res. 28, 2488\u20132492 (2022).","journal-title":"Clin. Cancer Res."},{"key":"711_CR164","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03348-5","volume":"22","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China. BMC Med. 22, 142 (2024).","journal-title":"BMC Med."},{"key":"711_CR165","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41409-025-02775-z","volume":"61","author":"K Kato","year":"2026","unstructured":"Kato, K. et al. Long-term follow-up of belumosudil as second or subsequent line of therapy for steroid-dependent\/resistant cGVHD: clinical outcomes from a Japanese study. Bone Marrow Transpl. 61, 225\u2013228 (2026).","journal-title":"Bone Marrow Transpl."},{"key":"711_CR166","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/ajh.27424","volume":"99","author":"Y Inamoto","year":"2024","unstructured":"Inamoto, Y. et al. An open-label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid-dependent\/steroid-resistant chronic GVHD. Am. J. Hematol. 99, 1917\u20131926 (2024).","journal-title":"Am. J. Hematol."},{"key":"711_CR167","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","volume":"391","author":"D Wolff","year":"2024","unstructured":"Wolff, D. et al. Axatilimab in recurrent or refractory chronic graft-versus-host disease. N. Engl. J. Med. 391, 1002\u20131014 (2024).","journal-title":"N. Engl. J. Med."},{"key":"711_CR168","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky, J. A. et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122, 2539\u20132549 (2013).","journal-title":"Blood"},{"key":"711_CR169","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","volume":"130","author":"D Miklos","year":"2017","unstructured":"Miklos, D. et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood 130, 2243\u20132250 (2017).","journal-title":"Blood"},{"key":"711_CR170","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1200\/JCO.22.00509","volume":"41","author":"DB Miklos","year":"2023","unstructured":"Miklos, D. B. et al. Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized phase III iNTEGRATE study. J. Clin. Oncol. 41, 1876\u20131887 (2023).","journal-title":"J. Clin. Oncol."},{"key":"711_CR171","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41375-022-01701-2","volume":"36","author":"HT Greinix","year":"2022","unstructured":"Greinix, H. T., Ayuk, F. & Zeiser, R. Extracorporeal photopheresis in acute and chronic steroid-refractory graft-versus-host disease: an evolving treatment landscape. Leukemia 36, 2558\u20132566 (2022).","journal-title":"Leukemia"},{"key":"711_CR172","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1182\/blood-2008-03-141481","volume":"112","author":"ME Flowers","year":"2008","unstructured":"Flowers, M. E. et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 112, 2667\u20132674 (2008).","journal-title":"Blood"},{"key":"711_CR173","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05052385 (2024)."},{"key":"711_CR174","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06663722 (2026)."},{"key":"711_CR175","first-page":"2932","volume":"141","author":"AG Koshy","year":"2023","unstructured":"Koshy, A. G. et al. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood 141, 2932\u20132943 (2023).","journal-title":"Blood"},{"key":"711_CR176","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/blood-2017-05-786137","volume":"130","author":"F Malard","year":"2017","unstructured":"Malard, F. et al. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. Blood 130, 2186\u20132195 (2017).","journal-title":"Blood"},{"key":"711_CR177","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1182\/blood-2013-04-495895","volume":"122","author":"C Cutler","year":"2013","unstructured":"Cutler, C. et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood 122, 1510\u20131517 (2013).","journal-title":"Blood"},{"key":"711_CR178","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1182\/bloodadvances.2021005552","volume":"6","author":"A Lazaryan","year":"2022","unstructured":"Lazaryan, A. et al. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Adv. 6, 259\u2013269 (2022).","journal-title":"Blood Adv."},{"key":"711_CR179","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-022-01240-4","volume":"15","author":"K Zhao","year":"2022","unstructured":"Zhao, K. et al. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J. Hematol. Oncol. 15, 22 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"711_CR180","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/sctm.20-0099","volume":"9","author":"E Boberg","year":"2020","unstructured":"Boberg, E. et al. Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: a phase II study. Stem Cell Transl. Med. 9, 1190\u20131202 (2020).","journal-title":"Stem Cell Transl. Med."},{"key":"711_CR181","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04189432 (2023)."},{"key":"711_CR182","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1182\/blood-2012-01-403428","volume":"120","author":"P Zerr","year":"2012","unstructured":"Zerr, P. et al. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood 120, 2909\u20132917 (2012).","journal-title":"Blood"},{"key":"711_CR183","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/bloodadvances.2017011239","volume":"1","author":"Z DeFilipp","year":"2017","unstructured":"DeFilipp, Z. et al. Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease. Blood Adv. 1, 1919\u20131922 (2017).","journal-title":"Blood Adv."},{"key":"711_CR184","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1158\/1078-0432.CCR-23-0666","volume":"29","author":"E Rodr\u00edguez-Arbol\u00ed","year":"2023","unstructured":"Rodr\u00edguez-Arbol\u00ed, E. et al. Targeting hedgehog signaling with glasdegib in patients with refractory sclerotic chronic GVHD: a report of two phase I\/II trials. Clin. Cancer Res. 29, 4057\u20134067 (2023).","journal-title":"Clin. Cancer Res."},{"key":"711_CR185","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1136\/annrheumdis-2012-201784","volume":"71","author":"S Weingartner","year":"2012","unstructured":"Weingartner, S. et al. Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. Ann. Rheum. Dis. 71, 1895\u20131899 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"711_CR186","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood.2020006892","volume":"137","author":"LM Curtis","year":"2021","unstructured":"Curtis, L. M. et al. A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. Blood 137, 896\u2013907 (2021).","journal-title":"Blood"},{"key":"711_CR187","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth, J. et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365, 2055\u20132066 (2011).","journal-title":"N. Engl. J. Med."},{"key":"711_CR188","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","volume":"128","author":"J Koreth","year":"2016","unstructured":"Koreth, J. et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood 128, 130\u2013137 (2016).","journal-title":"Blood"},{"key":"711_CR189","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1096\/fj.07-105627","volume":"22","author":"A Akhmetshina","year":"2008","unstructured":"Akhmetshina, A. et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 22, 2214\u20132222 (2008).","journal-title":"FASEB J."},{"key":"711_CR190","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1182\/blood-2013-05-494278","volume":"122","author":"A Olivieri","year":"2013","unstructured":"Olivieri, A. et al. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood 122, 4111\u20134118 (2013).","journal-title":"Blood"},{"key":"711_CR191","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1182\/blood-2014-02-554279","volume":"124","author":"CC Pai","year":"2014","unstructured":"Pai, C. C. et al. Treatment of chronic graft-versus-host disease with bortezomib. Blood 124, 1677\u20131688 (2014).","journal-title":"Blood"},{"key":"711_CR192","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.1182\/bloodadvances.2025016284","volume":"9","author":"T Caballero-Vel\u00e1zquez","year":"2025","unstructured":"Caballero-Vel\u00e1zquez, T. et al. Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers. Blood Adv. 9, 5528\u20135538 (2025).","journal-title":"Blood Adv."},{"key":"711_CR193","volume":"23","author":"AW Loren","year":"2025","unstructured":"Loren, A. W. et al. Hematopoietic cell transplantation, version 3.2025, NCCN clinical practice guidelines in oncology. J. Natl Compr. Cancer Netw. 23, e250047 (2025).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"711_CR194","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/10428194.2024.2409876","volume":"66","author":"J Caputo","year":"2025","unstructured":"Caputo, J. et al. Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies. Leuk. Lymphoma 66, 131\u2013138 (2025).","journal-title":"Leuk. Lymphoma"},{"key":"711_CR195","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1182\/blood-2016-08-693507","volume":"129","author":"KM Williams","year":"2017","unstructured":"Williams, K. M. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood 129, 448\u2013455 (2017).","journal-title":"Blood"},{"key":"711_CR196","doi-asserted-by":"publisher","first-page":"34","DOI":"10.6004\/jnccn.2023.7080","volume":"22","author":"AM Nelson","year":"2024","unstructured":"Nelson, A. M. et al. Group coping intervention in patients with chronic graft-versus-host disease: a pilot randomized clinical trial. J. Natl Compr. Cancer Netw. 22, 34\u201342 (2024).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"711_CR197","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/bmt.2015.316","volume":"51","author":"KM Williams","year":"2016","unstructured":"Williams, K. M. et al. The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. Bone Marrow Transpl. 51, 573\u2013580 (2016).","journal-title":"Bone Marrow Transpl."},{"key":"711_CR198","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","volume":"15","author":"M Tomblyn","year":"2009","unstructured":"Tomblyn, M. et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol. Blood Marrow Transpl. 15, 1143\u20131238 (2009).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"711_CR199","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.bbmt.2012.01.017","volume":"18","author":"J Tran","year":"2012","unstructured":"Tran, J. et al. Pulmonary rehabilitation for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Biol. Blood Marrow Transpl. 18, 1250\u20131254 (2012).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"711_CR200","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/j.chest.2020.05.557","volume":"158","author":"W Tang","year":"2020","unstructured":"Tang, W., Yu, T., Dong, T., Liu, T. & Ji, J. Nintedanib in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Chest 158, e89\u2013e91 (2020).","journal-title":"Chest"},{"key":"711_CR201","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1182\/blood-2016-05-715896","volume":"128","author":"C McDonald-Hyman","year":"2016","unstructured":"McDonald-Hyman, C. et al. Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood 128, 1013\u20131017 (2016).","journal-title":"Blood"},{"key":"711_CR202","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026446","author":"E Meyer","year":"2025","unstructured":"Meyer, E. et al. Donor regulatory T-cell therapy to prevent graft-versus-host disease. Blood https:\/\/doi.org\/10.1182\/blood.2024026446 (2025).","journal-title":"Blood"},{"key":"711_CR203","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05095649 (2024)."},{"key":"711_CR204","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04987333 (2024)."},{"key":"711_CR205","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03422627 (2023)."},{"key":"711_CR206","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamaoncol.2021.6846","volume":"8","author":"GS Guru Murthy","year":"2022","unstructured":"Guru Murthy, G. S. et al. Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors. JAMA Oncol. 8, 404\u2013411 (2022).","journal-title":"JAMA Oncol."},{"key":"711_CR207","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000735","volume":"6","author":"N Kutsch","year":"2022","unstructured":"Kutsch, N. et al. Sustained remission of relapsed diffuse large B-cell lymphoma after safe administration of CD19-directed CAR T-cells in a patient with chronic intestinal and pulmonal GvHD. Hemasphere 6, e735 (2022).","journal-title":"Hemasphere"},{"key":"711_CR208","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1182\/blood-2015-08-664250","volume":"127","author":"E Jacoby","year":"2016","unstructured":"Jacoby, E. et al. Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. Blood 127, 1361\u20131370 (2016).","journal-title":"Blood"},{"key":"711_CR209","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102377","volume":"67","author":"Y Luo","year":"2024","unstructured":"Luo, Y. et al. Donor-derived anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial. eClinicalMedicine 67, 102377 (2024).","journal-title":"eClinicalMedicine"},{"key":"711_CR210","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","volume":"390","author":"Y Hu","year":"2024","unstructured":"Hu, Y. et al. Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis. N. Engl. J. Med. 390, 1467\u20131480 (2024).","journal-title":"N. Engl. J. Med."},{"key":"711_CR211","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1182\/blood.2021015352","volume":"140","author":"M Burgos da Silva","year":"2022","unstructured":"Burgos da Silva, M. et al. Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease. Blood 140, 2385\u20132397 (2022).","journal-title":"Blood"},{"key":"711_CR212","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/bjh.19016","volume":"203","author":"N El Jurdi","year":"2023","unstructured":"El Jurdi, N. et al. Pre-transplant and longitudinal changes in faecal microbiome characteristics are associated with subsequent development of chronic graft-versus-host disease. Br. J. Haematol. 203, 288\u2013294 (2023).","journal-title":"Br. J. Haematol."},{"key":"711_CR213","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","volume":"125","author":"ME Flowers","year":"2015","unstructured":"Flowers, M. E. & Martin, P. J. How we treat chronic graft-versus-host disease. Blood 125, 606\u2013615 (2015).","journal-title":"Blood"},{"key":"711_CR214","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1182\/blood-2013-05-499806","volume":"122","author":"FL Wong","year":"2013","unstructured":"Wong, F. L. et al. Longitudinal trajectory of sexual functioning after hematopoietic cell transplantation: impact of chronic graft-versus-host disease and total body irradiation. Blood 122, 3973\u20133981 (2013).","journal-title":"Blood"},{"key":"711_CR215","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1164\/rccm.202109-2073IM","volume":"206","author":"M Sato","year":"2022","unstructured":"Sato, M. et al. Bronchiolitis obliterans syndrome after hematopoietic stem cell transplant diagnosed using ultrathin bronchoscopy. Am. J. Respir. Crit. Care Med. 206, e1\u2013e3 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"711_CR216","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1182\/blood-2006-02-003954","volume":"108","author":"CJ Fraser","year":"2006","unstructured":"Fraser, C. J. et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood 108, 2867\u20132873 (2006).","journal-title":"Blood"},{"key":"711_CR217","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","volume":"117","author":"J Pidala","year":"2011","unstructured":"Pidala, J. et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 117, 4651\u20134657 (2011).","journal-title":"Blood"},{"key":"711_CR218","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3324\/haematol.2018.192930","volume":"103","author":"SJ Lee","year":"2018","unstructured":"Lee, S. J. et al. Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica 103, 1535\u20131541 (2018).","journal-title":"Haematologica"},{"key":"711_CR219","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/sj.bmt.1700672","volume":"19","author":"RP McQuellon","year":"1997","unstructured":"McQuellon, R. P. et al. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transpl. 19, 357\u2013368 (1997).","journal-title":"Bone Marrow Transpl."},{"key":"711_CR220","first-page":"700.e1","volume":"28","author":"SJ Lee","year":"2022","unstructured":"Lee, S. J. et al. Correlation of patient-reported outcomes with clinical organ responses: data from the belumosudil chronic graft-versus-host disease studies. Transpl. Cell Ther. 28, 700.e1\u2013700.e6 (2022).","journal-title":"Transpl. Cell Ther."},{"key":"711_CR221","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1182\/blood.2024027334","volume":"145","author":"E Baumrin","year":"2025","unstructured":"Baumrin, E., Pidala, J., Mitchell, S. A., Onstad, L. & Lee, S. J. Development of the Lee Symptom Scale-Skin Sclerosis for chronic GVHD-associated sclerosis. Blood 145, 1321\u20131332 (2025).","journal-title":"Blood"},{"key":"711_CR222","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb7028","volume":"12","author":"J Strobl","year":"2020","unstructured":"Strobl, J. et al. Long-term skin-resident memory T cells proliferate in situ and are involved in human graft-versus-host disease. Sci. Transl. Med. 12, eabb7028 (2020).","journal-title":"Sci. Transl. Med."},{"key":"711_CR223","doi-asserted-by":"publisher","DOI":"10.1172\/JCI159229","volume":"132","author":"Z Liu","year":"2022","unstructured":"Liu, Z. et al. Reprogramming alveolar macrophage responses to TGF-\u03b2 reveals CCR2+ monocyte activity that promotes bronchiolitis obliterans syndrome. J. Clin. Invest. 132, e159229 (2022).","journal-title":"J. Clin. Invest."},{"key":"711_CR224","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1182\/blood.2024025036","volume":"145","author":"MC Zaiken","year":"2025","unstructured":"Zaiken, M. C. et al. Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHD. Blood 145, 2813\u20132827 (2025).","journal-title":"Blood"},{"key":"711_CR225","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1182\/blood-2015-09-668145","volume":"127","author":"H Jin","year":"2016","unstructured":"Jin, H. et al. Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. Blood 127, 2249\u20132260 (2016).","journal-title":"Blood"},{"key":"711_CR226","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103304","volume":"85","author":"A Quiambao","year":"2025","unstructured":"Quiambao, A. et al. World Health Organization\u2019s guidance for tracking non-communicable diseases towards Sustainable Development Goals 3.4: an initiative for facility-based monitoring. eClinicalMedicine 85, 103304 (2025).","journal-title":"eClinicalMedicine"},{"key":"711_CR227","doi-asserted-by":"publisher","first-page":"e569","DOI":"10.1016\/S2468-2667(22)00113-X","volume":"7","author":"TNA Winkelman","year":"2022","unstructured":"Winkelman, T. N. A., Dasrath, K. C., Young, J. T. & Kinner, S. A. Universal health coverage and incarceration. Lancet Public Health 7, e569\u2013e572 (2022).","journal-title":"Lancet Public Health"},{"key":"711_CR228","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1016\/S2352-3026(24)00174-1","volume":"11","author":"F Locatelli","year":"2024","unstructured":"Locatelli, F. et al. Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study. Lancet Haematol. 11, e580\u2013e592 (2024).","journal-title":"Lancet Haematol."}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00711-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00711-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00711-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:03:13Z","timestamp":1781161393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00711-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":228,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["711"],"URL":"https:\/\/doi.org\/10.1038\/s41572-026-00711-z","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"7 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.M. reports honoraria from Therakos\/Mallinckrodt, Janssen, Biocodex, Sanofi, Jazz Pharmaceuticals, Gilead, Novartis and Astellas, all outside the scope of this work. A.R reports honoraria from Kite and Gilead, all outside the scope of this work. M.M. reports grants, lecture honoraria and research support from Adaptive Biotechnologies, Amgen, Astellas, BMS-Celgene, GlaxoSmithKline, Janssen, Jazz Pharmaceuticals, Novartis, Pfizer, Takeda and Sanofi, all outside the scope of this work. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a0\n                      \n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"37"}}